While the COVID-19 pandemic may now be in the rearview mirror, healthcare remains a dynamic sector of growing importance. Thanks to longer life spans and continued innovation in disease treatments, the sector offers a long runway of growth. And our newest Best Dividend List pick happens to be one of the best on the block with over 50 years’ worth of dividend increases under its belt!
Our pick features a plethora of blockbuster drugs in its portfolio, including some of the bestselling of all time, which has provided billions of dollars worth of cash flow. Our pick pays one of the largest yields in the entire pharmaceutical sector.
In addition to those shareholder rewards, our pick has used the excess cash to fund innovation and build out its pipeline. New drugs in various hard-to-treat areas have been developed, while smart M&A has been conducted.
The end result is that our pick has plenty of muscle and cash flow potential to avoid any potential patent cliffs and generic drug competition. For investors, it offers a great high yield on innovation and continued healthcare demand.
In addition to biotech-focused pharmaceutical stocks, we have increased our positions in six other current picks while taking profits and reducing exposure on five other names.
You can check out the Best Dividend Stocks Model Portfolio to explore all the stocks.
